A Multicenter, Open-Label Safety Study of Natalizumab administered to Subjects with Relapsing Forms of Multiple Sclerosis who participated in STRATA.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2014
This article has no abstract
Epistemonikos ID: 951e35e6c021025636d5467cfa225f9af27f7494
First added on: Jan 22, 2025